Of note, in their model, they used both anti-CTLA-4 and anti-PD-1 inhibitors and found that the addition of either the class I specific HDAC inhibitor, entinostat, or DNMT inhibitor, azacitidine (5-AZA), significantly decreased metastases and tumor growth, and increased survival. Here, DNMT1 is linked to neoplasm.